Table 1.
Model Results
Year | Prevalence of HIV infection,% |
||||
Baseline CD4 cell count <350 cells/mm3 | ART initiation, CD4 cell count <500 cells/mm3 | Treat all in care | Test-and-treat all | ||
2009 | 24.7 | 24.7 | 24.7 | 24.7 | |
2014 | 25.1 | 22.9 | 21.9 | 20.9 | |
2019 | 25.5 | 21.7 | 19.4 | 17.5 | |
2029 | 26.2 | 21.8 | 17.1 | 12.8 | |
New HIV infections since 2009 | Baseline (CD4<350) | ART start CD4<500 | Treat all in care | Test-and-treat all | |
2014 | 3703 | 2149 | 1534 | 893 | |
2019 | 7446 | 4344 | 2896 | 1406 | |
2029 | 14,960 | 10,020 | 6739 | 2771 | |
HIV Infections Averted* | ART start CD4<500 | Treat all in care | Test-and-treat all | ||
2014 | Reference | 1554 | 2169 | 2810 | |
2019 | Reference | 3102 | 4550 | 6040 | |
2029 | Reference | 4940 | 8221 | 12,189 | |
Percent reduction in new HIV infectionsa | Reference | ART start CD4<500 | Treat all in care | Test-and-treat all | |
2014 | Reference | 42 | 59 | 76 | |
2019 | Reference | 42 | 61 | 81 | |
2029 | Reference | 33 | 55 | 81 |
HIV infections averted and percent reduction in new infections are relative to 2009 model estimates. Expansion of ART treatment strategies are assumed to start in 2009.